SR-044
- Generic Name
- SR-044
Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Ribocure Pharmaceuticals AB
- Target Recruit Count
- 120
- Registration Number
- NCT06797401
- Locations
- 🇸🇪
Lunds Universitetssjukhus, Lund, Sweden
🇸🇪Ribocure Clinic/Ribocure Pharmaceuticals AB, Mölndal, Sweden
🇸🇪Akademiska Sjukhuset Uppsala, Uppsala, Sweden
A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05539651
- Locations
- 🇦🇺
Q-Pharm Pty Limited, Brisbane, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath